Symptoms outweigh an in-range level
On day 5 of gentamicin, the client reports ringing in both ears (tinnitus), a sense of fullness, and unsteadiness when he walks. His trough levels (0.6 and 0.8 mg/L) are below the target of 1 mg/L, and his creatinine has barely changed (0.9 to 1.0 mg/dL). It is tempting to decide that the drug is safe. Aminoglycosides can damage the cochlea and the vestibular system even when trough levels are within range, so new ear symptoms are treated as possible toxicity. The nurse reports them before the next dose so the prescriber can review the drug.
How aminoglycoside ototoxicity happens
Gentamicin and other aminoglycosides accumulate in the fluids of the inner ear and damage the hair cells of the cochlea, which sense sound, and of the vestibular organs, which sense balance and head movement. Cochlear damage causes tinnitus, fullness, and high-frequency hearing loss; vestibular damage causes dizziness, imbalance, and unsteady walking. Gentamicin is particularly vestibulotoxic. The damage can be permanent, and risk rises with older age, longer courses, prior hearing loss, and other ototoxic drugs such as loop diuretics. This client is 70, already has hearing loss, and is in a high-risk group.
| Data | Value | Interpretation |
|---|
| Trough | 0.6 and 0.8 mg/L (target below 1) | In range, but does not exclude toxicity |
| Creatinine | 0.9 to 1.0 mg/dL | Stable kidney function |
| Tinnitus, fullness, unsteadiness | New on day 5 | Possible cochlear and vestibular toxicity |
Why the other evaluations are wrong
Saying there is no toxicity because the trough is in range relies on a number while ignoring symptoms. Saying there is no toxicity because kidney function is unchanged confuses two adverse effects: stable kidneys lower the risk of accumulation but do not rule out ototoxicity. Blaming age-related hearing loss does not fit, because presbycusis develops slowly over years and does not cause sudden tinnitus with imbalance.
Nursing monitoring on aminoglycosides
The nurse asks every day about tinnitus, fullness, hearing change, and dizziness, observes gait, monitors creatinine, urine output, and levels, and avoids combining with other ototoxic or nephrotoxic drugs when possible. Fall precautions are started for unsteadiness.
Exam takeaway
Watch out A therapeutic drug level does not make an aminoglycoside safe. New tinnitus, fullness, or dizziness is reported before the next dose.